MiMedx targets $340M-$360M 2026 revenue while navigating reimbursement changes and boosting surgical growth
Source: SeekingAlpha
2026-02-25 19:08:30 ET
More on MiMedx Group
- MiMedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript
- MiMedx Group Non-GAAP EPS of $0.14 beats by $0.03, revenue of $118.1M beats by $11.32M
- Organogenesis drops as Medicare to pull skin substitute LCDs (update)
- Seeking Alpha’s Quant Rating on MiMedx Group
- Historical earnings data for MiMedx Group
Read the full article on Seeking Alpha
For further details see:
MiMedx targets $340M–$360M 2026 revenue while navigating reimbursement changes and boosting surgical growth
MiMedx Group Inc
NASDAQ: MDXG
MDXG Trading
2.81% G/L:
$4.575 Last:
312,011 Volume:
$4.59 Open:
MDXG Latest News
March 05, 2026 08:00:00 am
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
February 25, 2026 04:01:00 pm
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
MDXG Stock Data
$773,833,781
117,296,910
0.16%
76
N/A
Biotechnology & Life Sciences
Healthcare
US
Marietta
